Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset Published September 2019 Citation Backenroth D, Shao C, Li G, Huang L,Pruitt SK, Castellanos EH, Frampton GM, Carson KR, Snow T, Singal G, Fabrizio D, Alexander BM, Jin FJ, Zhou W. . ESMO Annual Congress. . https://www.sciencedirect.com/science/article/pii/S0923753419600062 Authors:Backenroth D, Shao C, Li G, Huang L,Pruitt SK, Castellanos EH, Frampton GM, Carson KR, Snow T, Singal G, Fabrizio D, Alexander BM, Jin FJ, Zhou W Sources:ESMO Annual Congress Share Posted inPublicationsDrug discoveryTumor agnostic More publicationsESMOOctober 2025Treatment duration and subsequent treatments of first-line CDK4/6i plus aromatase inhibitor for HR+/HER2- metastatic breast cancer in US routine clinical practiceBrufsky A, Layman R, Liu X, et al.Publication summaryPublicationsComparative effectivenessBreast cancerESMOOctober 2025Real-world treatment patterns and outcomes in US patients with neurotrophic tyrosine receptor kinase–positive solid tumorsSu, I, Flores Avile C, Huang P, et al. Publication summaryPublicationsTreatment patternsESMO OpenSeptember 2025Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practiceRugo H, Layman R, Lynce F, et al.Publication summaryPublicationsComparative effectivenessMetastatic breast cancerBreast cancer